Table 1. Demographic, virological and clinical characteristics of study subjects.
| Variables | HIV co-infected (n = 48) | HBV mono-infected (n = 95) |
Total (n = 143) |
P -value* |
|
|---|---|---|---|---|---|
| Liver disease patients (n = 52) | Blood donors (n = 43) |
||||
| Demographic characteristics | n(%) | n(%) | n(%) | n(%) | |
| Age: Median(Interquartile range, IQR) | 34(28–41) | 35(25–45) | 28(22–35) | 32(25–40) | 0.004 |
| Sex: Male | 22(45.8) | 40(76.9) | 37(86.0) | 99(69.2) | <0.001 |
| Female | 26(54.2) | 12(23.1) | 6(14.0) | 44(30.8) | |
| Virological characteristics | |||||
| HBeAg status: Negative | 26(54.2) | 31(59.6) | 32(74.4) | 89(62.2) | 0.12 |
| Positive | 22(45.8) | 21(40.4) | 11(25.6) | 54(37.8) | |
| Plasma HBV DNA viral load (logIU/ml):Median(IQR) | 6.7(3.1–8.4) | 5.5(4.1–6.8) | 3.3(2.8–3.9) | 4.4(3.2–7.2) | 0.05 |
| HBV genotypes: A | 26(54.2) | 31(59.6) | 29(67.4) | 86(60.1) |
0.67 |
| D | 21(43.8) | 21(40.4) | 14(32.6) | 56(39.2) | |
| E | 1(2.1) | 0(0.0) | 0(0.0) | 1(0.7) | |
| HBV drug resistance mutations†:Undetected | 20(41.7) | 43(82.7) | 33(76.7) | 96(67.1) | <0.001 |
| Detected | 28(58.3) | 9(17.3) | 10(23.3) | 47(32.9) | |
| HBsAg escape mutations†: Undetected | 8(16.7) | 15(28.8) | 13(30.2) | 36(25.2) | 0.25 |
| Detected | 40(83.3) | 37(71.2) | 30(69.8) | 107(74.8) | |
|
ART related clinical characteristics (for HIV co-infected patients only) |
|||||
| WHO staging: I & II | 40(83.3) | - | - | 40(83.3) | - |
| III & IV | 8(16.6) | - | - | 8(16.6) | - |
| ART: Experienced | 23(47.9) | - | - | 23(47.9) | - |
| Naïve | 25(52.1) | - | - | 25(52.1) | - |
| ART follow up (in years) Median(IQR) | 3.8(1.7–7.5) | - | - | 3.8(1.7–7.5) | - |
| Clinical status (for liver disease patients only) | |||||
| Undefined | - | 17(32.7) | - | 17(32.7) | - |
| Hepatocelluar carcinoma | - | 8(15.4) | - | 8(15.4) | - |
| Ascites | - | 6 (11.5) | - | 6 (11.5) | - |
| Cirrhosis | - | 4(7.7) | - | 4(7.7) | - |
| Acute hepatitis +Jaundice+ chronic hepatitis | - | 8(15.4) | - | 8(15.4) | - |
| Complications with other infections/conditions& | - | 9(17.3) | - | 9(17.3) | - |
†Major mutations conferring multi-drug resistance and HBsAg escape mutations as reported before [24].
&Schistosomiasis and hepato/splenomegaly conditions.
Column cells indicated with a sign ‘–’ means not applicable.
*P-value indicated the statistical variances among the three groups.